BY PHILIP MADSEN
-
FDA approves blood test for diagnosing Alzheimer’s
The authorization is being called a “video game changer” and according to one expert can lead the way for medicines to deal with mental deterioration.
-
Novo Nordisk shows promising results for weekly growth hormone
The firm examined the long-acting development hormonal agent Sogroya, offered when a week, versus Norditropin, utilized once daily.
-
Report: Novo Nordisk’s phase-out of insulin pens could affect children in developing countries
According to Novo Nordisk, the terminating of human insulin pens in particular nations is because of worldwide “ability restrictions”.
-
EU and US agree to intensify tariff talks
The EU and the United States await settlements on profession and tolls, states EU Profession Commissioner Maros Sefcovic.
-
Top advisor: Trump’s price intervention could impact access to medicines in other countries
The cost suppression on medications introduced by Trump can lead drugmakers to go down launches in nations aside from the United States– and will certainly strike more diffic…
-
Gubra maintains outlook despite revenue slide
Den samlede omsætning faldt med 12 pct. sammenlignet med samme kvartal sidste år.
-
WSA CEO: Product launches will compensate for tough market
WS-Audiology’s chief executive officer is positive that brand-new launches can save development and develop a “extremely solid 3rd and 4th quarter”.
-
Genmab CEO predicts billion-dollar sales from three drug candidates
In spite of a shelved task that has actually stressed experts, Genmab anticipates considerable development chances in 3 various other medications.
-
Strategic mistake in the US makes matters worse for Demant: “Sometimes you misjudge the situation a bit”
The listening device titan has actually not yet worked out a contract with vital United States representatives, that in 2015 determined to eliminate the business’s items from…
-
GN sticks to debt plan despite massive challenges
After seeing huge decreases over the previous 2 years, the firm’s interest-bearing financial debt boosted once more in the very first quarter.